Certara (NASDAQ:CERT) Stock Price Down 4.8% After Analyst Downgrade

Certara, Inc. (NASDAQ:CERT - Get Free Report) fell 4.8% during trading on Tuesday after KeyCorp lowered their price target on the stock from $18.00 to $15.00. KeyCorp currently has an overweight rating on the stock. Certara traded as low as $10.65 and last traded at $10.60. 207,751 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 1,474,408 shares. The stock had previously closed at $11.14.

Other equities research analysts have also issued research reports about the stock. Morgan Stanley began coverage on shares of Certara in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price objective for the company. JMP Securities reissued a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. Robert W. Baird upped their price objective on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Finally, Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $11.00 to $14.00 in a report on Thursday, May 8th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $15.29.

Institutional Investors Weigh In On Certara

A number of institutional investors have recently made changes to their positions in CERT. The Manufacturers Life Insurance Company boosted its stake in shares of Certara by 3.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company's stock valued at $253,000 after purchasing an additional 823 shares during the period. Private Advisor Group LLC boosted its stake in shares of Certara by 4.0% in the first quarter. Private Advisor Group LLC now owns 24,517 shares of the company's stock valued at $243,000 after purchasing an additional 949 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after purchasing an additional 1,047 shares during the period. Invesco Ltd. boosted its stake in shares of Certara by 0.3% in the first quarter. Invesco Ltd. now owns 394,037 shares of the company's stock valued at $3,901,000 after purchasing an additional 1,285 shares during the period. Finally, B. Metzler seel. Sohn & Co. AG boosted its stake in shares of Certara by 1.4% in the first quarter. B. Metzler seel. Sohn & Co. AG now owns 115,592 shares of the company's stock valued at $1,144,000 after purchasing an additional 1,636 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Trading Down 4.2%

The company's 50 day moving average price is $11.32 and its 200 day moving average price is $11.86. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.78 and a quick ratio of 2.78. The firm has a market cap of $1.64 billion, a PE ratio of -505.00 and a beta of 1.43.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The business had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. During the same quarter last year, the firm posted $0.10 earnings per share. The business's revenue for the quarter was up 9.7% compared to the same quarter last year. As a group, analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.